7
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Systematic detection of mosaicism by using digital NGS reveals three new MEN1 mosaicisms

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Mosaicism is a feature of several inherited tumor syndromes. Only a few cases of mosaicism have been described in multiple endocrine neoplasia type 1 (MEN1). Next-generation sequencing (NGS) offers new possibilities for detecting mosaicism. Here, we report the first study to systematically look for MEN1 mosaicism, using blood DNA, in MEN1-suspected patients but without MEN1 pathogenic variants (PV) in a heterozygous state.

          Methods

          Digital targeted NGS, including unique molecular identifiers (UMIs), was performed in routine practice, and the analytic performance of this method was verified.

          Results

          Among a cohort of 119 patients harboring from 2 to 5 MEN1 lesions, we identified 3 patients with MEN1 mosaic PVs. The allele frequencies ranged from 2.3 to 9.5%. The detection rate of MEN1 mosaicism in patients bearing at least 3 MEN1 lesions was 17% (3/18). No cases were detected in patients with two lesions.

          Conclusion

          We report here three new cases with MEN1 mosaicism. This study examined the performance of UMI in the diagnosis of MEN1 mosaicism in routine practice, and our results underline that the frequency of mosaicism is probably underestimated in patients with suspected MEN1.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Counting absolute numbers of molecules using unique molecular identifiers.

          Counting individual RNA or DNA molecules is difficult because they are hard to copy quantitatively for detection. To overcome this limitation, we applied unique molecular identifiers (UMIs), which make each molecule in a population distinct, to genome-scale human karyotyping and mRNA sequencing in Drosophila melanogaster. Use of this method can improve accuracy of almost any next-generation sequencing method, including chromatin immunoprecipitation-sequencing, genome assembly, diagnostics and manufacturing-process control and monitoring.
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

            The aim was to provide guidelines for evaluation, treatment, and genetic testing for multiple endocrine neoplasia type 1 (MEN1). The group, which comprised 10 experts, including physicians, surgeons, and geneticists from international centers, received no corporate funding or remuneration. Guidelines were developed by reviews of peer-reviewed publications; a draft was prepared, reviewed, and rigorously revised at several stages; and agreed-upon revisions were incorporated. MEN1 is an autosomal dominant disorder that is due to mutations in the tumor suppressor gene MEN1, which encodes a 610-amino acid protein, menin. Thus, the finding of MEN1 in a patient has important implications for family members because first-degree relatives have a 50% risk of developing the disease and can often be identified by MEN1 mutational analysis. MEN1 is characterized by the occurrence of parathyroid, pancreatic islet, and anterior pituitary tumors. Some patients may also develop carcinoid tumors, adrenocortical tumors, meningiomas, facial angiofibromas, collagenomas, and lipomas. Patients with MEN1 have a decreased life expectancy, and the outcomes of current treatments, which are generally similar to those for the respective tumors occurring in non-MEN1 patients, are not as successful because of multiple tumors, which may be larger, more aggressive, and resistant to treatment, and the concurrence of metastases. The prognosis for MEN1 patients might be improved by presymptomatic tumor detection and undertaking treatment specific for MEN1 tumors. Thus, it is recommended that MEN1 patients and their families should be cared for by multidisciplinary teams comprising relevant specialists with experience in the diagnosis and treatment of patients with endocrine tumors.
              • Record: found
              • Abstract: found
              • Article: not found

              Positional cloning of the gene for multiple endocrine neoplasia-type 1.

              Multiple endocrine neoplasia-type 1 (MEN1) is an autosomal dominant familial cancer syndrome characterized by tumors in parathyroids, enteropancreatic endocrine tissues, and the anterior pituitary. DNA sequencing from a previously identified minimal interval on chromosome 11q13 identified several candidate genes, one of which contained 12 different frameshift, nonsense, missense, and in-frame deletion mutations in 14 probands from 15 families. The MEN1 gene contains 10 exons and encodes a ubiquitously expressed 2.8-kilobase transcript. The predicted 610-amino acid protein product, termed menin, exhibits no apparent similarities to any previously known proteins. The identification of MEN1 will enable improved understanding of the mechanism of endocrine tumorigenesis and should facilitate early diagnosis.

                Author and article information

                Journal
                Endocr Connect
                Endocr Connect
                EC
                Endocrine Connections
                Bioscientifica Ltd (Bristol )
                2049-3614
                14 October 2022
                01 November 2022
                : 11
                : 11
                : e220093
                Affiliations
                [1 ]Aix Marseille Univ , APHM, INSERM, MMG, Laboratory of Molecular Biology Hospital La Conception, Marseille, France
                [2 ]Univ. Lille , CNRS, Inserm, CHU Lille, UMR9020-U1277 – CANTHER – Cancer – Heterogeneity Plasticity and Resistance to Therapies, Lille, France
                [3 ]Service d’Endocrinologie , Centre Hospitalier Universitaire, Hôpital du Haut Levêque, Pessac, France
                [4 ]Endocrinology , Diabetology and Nutrition Unit, University Hospital of Reims, Reims, France
                [5 ]Inserm/CNRS UMR 1283/8199 , Pasteur Institute of Lille, EGID, Lille, France
                [6 ]Laboratory of Molecular Biology , Hospital La Conception, APHM, Marseille, France
                [7 ]Service Endocrinologie , CHU de Nancy, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France
                [8 ]CHU Lille , Service de Biochimie et Biologie Moléculaire ‘Hormonologie, Métabolisme-Nutrition, Oncologie’, Lille, France
                [9 ]Univ. Lille , Inserm, CHU Lille, U1286 – Infinite – Institute for Translational Research in Inflammation, Lille, France
                [10 ]Department of Gastroenterology and Digestive Oncology , Reims University Hospital, Reims, France
                [11 ]Aix Marseille Univ , APHM, INSERM, MMG, Department of Endocrinology, Hospital La Conception, Marseille, France
                Author notes
                Correspondence should be addressed to P Romanet: pauline.romanet@ 123456univ-amu.fr
                Author information
                http://orcid.org/0000-0002-6120-1098
                http://orcid.org/0000-0002-8440-0030
                http://orcid.org/0000-0003-1775-9569
                Article
                EC-22-0093
                10.1530/EC-22-0093
                9578105
                36112497
                9995167d-eb25-48ab-b4a8-b33bad1697b7
                © The authors

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 02 September 2022
                : 16 September 2022
                Categories
                Research

                mosaicism,men1,ngs,unique molecular identifier,mosaic,deep-sequencing,de novo,digital ngs,thymic tumor,pituitary adenoma,hyperparathyroidism,pancreatic neuroendocrine tumor

                Comments

                Comment on this article

                Related Documents Log